Abstract
A systematic review relating to muscle invasive bladder cancer and was conducted. This was to identify the molecular basis of muscle invasive disease. The search strategy aimed to identify all references related to bladder cancer AND muscle invasive disease AND molecular basis. Search terms used were as follows: (Bladder cancer) AND (muscle invasive disease) AND (Molecular Basis). The following databases were screened from 1989 to June 2020. The Molecular Basis of Bladder Cancer—Precision Diagnostics and Treatment, PIK3CA Mutations in Muscle Invasive Bladder Cancer, Epidermal Growth Factor in Muscle Invasive Bladder Cancer, P53, pRB and RAS in Muscle Invasive Bladder Cancer, Transcriptome Profiling in Muscle Invasive Bladder Cancer, Methylation Status in Bladder Cancer, The Cancer Genome Project and the Molecular Basis of Bladder Cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moher D, Liberati A, Tetzlaff J, Altman DG. “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The Prisma Statement.” [In English]. BMJ (Online) 339, no. 7716 (08 Aug 2009):332–36.
Mays N, Pope C, Popay J. “Systematically Reviewing Qualitative and Quantitative Evidence to Inform Management and Policy-Making in the Health Field.” [In English]. Journal of Health Services Research and Policy 10, no. SUPPL. 1 (July 2005):6–20.
Su H, Jiang H, Tao T, Kang X, Zhang X, Kang D, Li S, Li C, Wang H, Yang Z, Zhang J, Li C. Hope and challenge: precision medicine in bladder cancer. Cancer Med. 2019;8(4):1806–16.
Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol. 2019;247(5):563–73.
Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 2019;8(5):e1581556.
Smith K, Fennelly JA, Neal DE, Hall RR, Harris AL. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res. 1989;49(21):5810–5.
Al Hussain TO, Akhtar M. Molecular basis of urinary bladder cancer. Adv Anat Pathol. 2013;20(1):53–60.
Zhang S, Liu Y, Liu Z, Zhang C, Cao H, Ye Y, Wang S, Zhang Y, Xiao S, Yang P, Li J, Bai Z. Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing. PLoS One. 2014;9(3):e91466.
Beukers W, Kandimalla R, Masius RG, Vermeij M, Kranse R, van Leenders GJ, Zwarthoff EC. Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. Mod Pathol. 2015;28(4):515–22.
Creighton CJ. The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Rev Anticancer Ther. 2018;18(10):973–80.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Ventii, K., Bahl, A., Persad, R., Motiwala, H., Albala, D. (2021). The Molecular Basis of Muscle Invasive Bladder Cancer. In: Management of Muscle Invasive Bladder Cancer. Management of Urology. Springer, Cham. https://doi.org/10.1007/978-3-030-57915-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-57915-9_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57914-2
Online ISBN: 978-3-030-57915-9
eBook Packages: MedicineMedicine (R0)